Source
CPS Research, 3 Todd Campus, West of Scotland Science Park, Glasgow, G20 0KA, Scotland. alangwade@fastmail.fm
Abstract
BACKGROUND:
Clinical data show that poor quality, rather than quantity, of sleep corresponds negatively to measures of health, well-being and satisfaction with life. However, until now treatment of insomnia has primarily targeted quantity of sleep. PR (prolonged release)-melatonin offers a new treatment option in insomnia.
OBJECTIVES:
To provide an overview of PR-melatonin, the first melatonin receptor agonist to be granted marketing authorisation in Europe as monotherapy for the treatment of primary insomnia in patients aged > 55 years.
METHODS:
Review data published in peer review journals and the EMEA (European Medicines Agency) website.
RESULTS/CONCLUSION:
PR-melatonin significantly improves morning alertness and quality of sleep compared with placebo. There are no safety concerns.